Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01374906 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

A Phase 3 study of Cushing's Disease, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
150
Enrollment target
20
Study locations

NCT01374906 is a Phase 3 study of Cushing's Disease that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 150 participants, above the 102-participant average among 5 other Cushing's Disease trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01374906, a Phase 3 study of Cushing's Disease, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
150 participants
Enrollment target
20
Study locations

Study Summary

This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.

Conditions Studied

Cushing's Disease

Interventions

  • DRUG pasireotide LAR
  • DRUG SOM230 LAR 30 mg
  • DRUG SOM230 LAR 10 mg

Study Locations (20)

Other

  • Novartis Investigative Site - Buenos Aires
  • Novartis Investigative Site - Córdoba
  • Novartis Investigative Site - Brussels
  • Novartis Investigative Site - Ghent
  • Novartis Investigative Site - Leuven

California

  • University of California at Los Angeles UCLA Tiverton - Los Angeles
  • Harbor-UCLA Medical Center LA Biomed - Torrance

Arizona

  • ClinTriCo - Phoenix

Georgia

  • Emory University School of Medicine/Winship Cancer Institute G2304 - C2301 - Atlanta

Maryland

  • Pituitary Center, Division of Endocrinology SC - Baltimore

Michigan

  • University of Michigan Comprehensive Cancer Center SC-2 - Ann Arbor

New York

  • Mount Sinai School of Medicine Mt. Sinai Medical Center - New York

Oregon

  • Oregon Health & Sciences University DeptofOregonHealth&Sciences(2) - Portland

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2011-11-04
Est. Completion 2016-12-21
Phase Phase 3

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01374906

The ClinicalTrials.gov registry entry for NCT01374906 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 102-participant average among 5 other Cushing's Disease trials with a reported enrollment target (47% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cushing's Disease appearing as the primary indexed condition, and to 3 interventions - of which pasireotide LAR is the first listed.

NCT01374906 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT01374906 about?

NCT01374906 is a clinical study titled "Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease". This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.

What is the current status of trial NCT01374906?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2011-11-04. Estimated completion is 2016-12-21.

What conditions does trial NCT01374906 study?

This clinical trial studies the following conditions: Cushing's Disease.

What interventions are being tested in trial NCT01374906?

The interventions under investigation include: pasireotide LAR (DRUG), SOM230 LAR 30 mg (DRUG), SOM230 LAR 10 mg (DRUG).

Who is sponsoring clinical trial NCT01374906?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01374906 being conducted?

This trial has 20 study locations across Arizona, California, Georgia, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cushing's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cushing's Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.